GRAYZEL DAVID S. — SEC Form 4 filings
SEC reporting owner CIK 1732786. 9 Form 4 filings on record with FilingPulse; latest filed 2026-07-21.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-03-27 to 2026-07-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 11,882 shares, $334,478 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 11,882 shares @ $28.15 ($334,478) in Aerovate Therapeutics, Inc., filed 2024-04-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aerovate Therapeutics, Inc. (AVTE) | Director | 2 | — | 1 leg · 11,882 sh · $334,478 | 1 |
| Q32 Bio Inc. (QTTB) | Director | 7 | — | — | 13 |
Form 4 filings — GRAYZEL DAVID S.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-21 | 4/A | Q32 Bio Inc. (QTTB) | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 16,363 (derivative) @ $2.75 | EDGAR |
| 2025-10-27 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Q32 Bio Inc. (QTTB) | Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 · Disposition to issuer (D): 2,569 (derivative) @ $0 · Grant/award (A): 2,569 (derivative) @ $0 · Grant/award (A): 18,595 (derivative) @ $0 · Disposition to issuer (D): 18,595 (derivative) @ $0 · +1 more | EDGAR |
| 2024-08-14 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 2,569 (derivative) @ $13.42 | EDGAR |
| 2024-06-07 | 4 | Aerovate Therapeutics, Inc. (AVTE) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-04-11 | 4 | Aerovate Therapeutics, Inc. (AVTE) | Sale (S): 11,882 @ $28.15 | EDGAR |
| 2024-03-27 | 4 | Q32 Bio Inc. (QTTB) | Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1732786 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →